The Kaplan-Meir’s estimation of survival at 36 months was higher in patients with MPM (24% vs. 8% (p = 0.002) (Figure 1), WT-KRAS tumors (31% vs. 15%; p < 0.001) (Figure 2), N0 stage (30% vs. 19%; p < 0.001), T3 stage tumors (18% vs. 19% in T4A and 3% in T4B; p > 0.001) and tumors with classic adenocarcinoma histology (18% vs. 8%; p = 0.011). The gene discussed is KRAS; the disease is adenocarcinoma.